Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Active not recruiting 2Recruiting 1

Sponsor Class

NIH 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Colorectal Neoplasms 25Ovarian Neoplasms 19Neoplasms 12Fallopian Tube Neoplasms 12Carcinoma, Hepatocellular 11Endometrial Neoplasms 7Neoplasm Metastasis 6Colonic Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Glioblastoma 4Brain Neoplasms 4Squamous Cell Carcinoma of Head and Neck 3Rectal Neoplasms 3Lung Neoplasms 3Liver Neoplasms 3Digestive System Neoplasms 3Uterine Cervical Neoplasms 2Sarcoma 2Recurrence 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Mouth Neoplasms 2Lymphoid Interstitial Pneumonia 2Intestinal Neoplasms 2Gastrointestinal Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Ovarian Epithelial 2Brenner Tumor 2Breast Neoplasms 2Biliary Tract Neoplasms 2Astrocytoma 2

Interventions

Bevacizumab 3durvalumab 2atezolizumab 2Hepatectomy 2tremelimumab 1trastuzumab deruxtecan 1pembrolizumab 1Whole Genome Sequencing 1Standard of Care 1Specimen Handling 1Radionuclide Imaging 1Platinum 1Ipilimumab 1Immunotherapy 1Immunoglobulin G 1IMC-001 1Granulocyte-Macrophage Colony-Stimulating Factor 1Gemcitabine 1Disulfides 1Diathermy 1Cisplatin 1Cell- and Tissue-Based Therapy 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Liver Neoplasms × Bevacizumab × 30 days × Clear all
NCT03937830 2026-06-05

Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma

National Institutes of Health Clinical Center (CC)

Phase 2 Active not recruiting
27 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT05211323 2026-06-03

A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
88 enrolled
Gastrointestinal

Liver Neoplasms

NCT06096779 2026-06-01

Kirros

Genentech, Inc.

Phase 2 Recruiting
30 enrolled
Gastrointestinal

Digestive System Neoplasms, Fatty Liver, Fibrosis, Carcinoma, Hepatocellular, Liver Diseases, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡